Switzerland’s president is lobbying Trump administration officials in Washington this week, as concern mounts over the double ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Aristotle Capital’s International Equity ADR Composite posted a total return of 4.05% gross of fees, underperforming the MSCI ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

In today's Pharmalittle roundup, we're reading about Roche and Merck struggles with tariffs, NEJM quizzed by U.S. attorney, ...

U.S. drugmakers Bristol Myers and Merck & Co, and their European counterparts Sanofi and Roche all reported first-quarter ...

Clinical-stage company targeting fundamental drivers of inflammation, autoimmunity and fibrosis, founded by Versant Ventures and Novartis Venture Fund- ...

Increased adoption of expanded carrier screening, improved access to cutting-edge DNA sequencing, and rising demand for early genetic disease detection are reshaping the global carrier screening ...

Granite Bio is ready to rock ‘n’ roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

Brabeck-Letmathe, 80, spent his career at Nestlé. He became a controversial figure after sharing his views on water as a ...

The pharmaceutical and diagnostics company slightly exceeded expectations in the first quarter, driven by its pharmaceutical ...

Repertoire will obtain an upfront payment of $35m from Genentech, with the potential for up to $730m in additional milestones ...